Preparation and application of Golgi protein 73scFV antibody

The GP73 protein scFv antibody was prepared through phage display technology, combined with magnetic microparticle chemiluminescence kit, and solved the problems of long time, poor performance and insufficient epitope recognition in the prior art GP73 antibody preparation and detection, achieving rapid, stable and high GP73 detection of sensitivity.

CN118955708AActive Publication Date: 2024-11-15HUNAN LAITUOFU BIOTECHNOLOGY CO LTD

Patent Information

Application Number
CN202410982183.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-15
Estimated Expiration
2044-07-22

AI Technical Summary

Technical Problem

The prior art has problems such as long time, poor repeat production performance, low cell fusion efficiency, unstable antibody and long detection time when preparing GP73 antibodies, and cannot effectively identify all epitopes of GP73 protein, affecting the sensitivity and specificity of detection. .

Method used

The GP73 protein scFv antibody was prepared by phage display technology, and mice were immunized by human full-length GP73 sequence. The scFv gene was amplified by overlapping PCR, and an antibody library was constructed through phage display to screen out high-affinity SGA-1 and SGA- 2 antibodies were tested in combination with magnetic microparticle chemiluminescence kit.

Benefits of technology

It significantly saves preparation time, improves the stability and detection sensitivity of the antibody, shortens the detection time, expands the linear range, avoids HAMA reactions, and improves the reliability and specificity of the detection results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004956401120000051
    Figure BDA0004956401120000051
  • Figure BDA0004956401120000061
    Figure BDA0004956401120000061
  • Figure BDA0004956401120000071
    Figure BDA0004956401120000071
Patent Text Reader

Abstract

The invention relates to the field of antibody preparation and in-vitro diagnostic reagents, in particular to a GP73 protein scFV antibody prepared on the basis of a phage display technology and application of a magnetic particle chemiluminescence kit developed on the basis of the antibody to detection of the GP73 content in human serum. Compared with products of the same type, the scFv antibody obtained by the invention and a detection product developed based on the scFv antibody have a wider linear range and better detection sensitivity, the operation is simple, the detection time does not exceed 30 minutes, and the detection result is more stable and reliable.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of antibody preparation and in vitro diagnostic reagents, and specifically to the preparation of GP73 protein scFV antibody based on phage display technology, and the development of a magnetic particle chemiluminescence kit based on the antibody for the detection of GP73 content in human serum. Background Art

[0002] Golgi glycoprotein 73 (GP73) is a type of transmembrane protein discovered on the Golgi apparatus in recent years. Its relative molecular weight in protein electrophoresis is 73KD, so it is named GP73. GP73 is mainly expressed in bile duct epithelial cells, and is not expressed or expressed at very low levels in normal hepatocytes. In recent years, research data have shown that in the development of liver diseases such as cirrhosis, the expression of GP73 shows a significant upward trend. Specifically, the expression of GP73 gradually increases from acute and chronic hepatitis to cirrhosis, and is highest in cirrhotic tissues. Comprehensive research data show that GP73 has the potential to become a new serum marker for cirrhosis.

[0003] Cirrhosis is an important cause of morbidity and mortality in patients with chronic liver disease. Cirrhosis can lead to hepatocellular carcinoma and liver decompensation, including ascites, hepatic encephalopathy and varicose vein rupture, cardiac dysfunction, etc., and is associated with 2.4% of mortality worldwide each year. The main causes of cirrhosis include hepatitis B virus and hepatitis C virus infection, alcohol-related liver disease and fatty liver disease. According to the analysis data on cirrhosis and chronic liver disease provided by the Global Burden of Disease (GBD) database, the estimated number of patients with compensated cirrhosis worldwide is 112 million. The global disease burden of cirrhosis remains high, and the number of cirrhosis-related deaths and decompensated cirrhosis cases is expected to continue to rise in the next decade.

[0004] The accuracy of in vitro detection of Golgi protein 73 content is highly dependent on the quality of the GP73 antibody used. At present, almost all GP73 antibodies mentioned in existing patents are obtained using hybridoma technology. Although this technology is widely used, it still has some technical shortcomings, such as long preparation time, poor repetitive production performance, low fusion efficiency of spleen cells and myeloma cells, unstable production of hybridoma cells obtained, large batch differences, etc. In addition, hybridoma technology cannot prepare antibodies against non-immunogenic or highly toxic antigens, and the antibodies produced often need to be humanized, and the antibody preparation process is extremely cumbersome.

[0005] CN101735319B discloses a monoclonal antibody against GP73 protein and its preparation method. The GP73 antibody is prepared using common hybridoma technology, which is time-consuming and has a cumbersome screening process; cell fusion and hybridoma separation efficiency is low; hybridoma cell lines are unstable in culture genetics; the prepared mouse-derived antibodies are easily recognized by the human immune system and produce HAMA reactions; there are individual differences in hybridoma cell immunized animals, and the antibody differences between different batches are large. The two methods mentioned in the patent, namely the standard enzyme-linked immunosorbent assay and the chemiluminescent immunoassay, have a long detection time of about 70 minutes, and the overall operation process is complicated, and it is purely manual operation, with large human interference factors. In addition, the patent lacks necessary descriptions of the preparation of GP73 monoclonal antibodies, especially the acquisition of epitopes covered by GP73 monoclonal antibodies, but the coverage of epitopes plays a very important role in the sensitivity and specificity of GP73 detection.

[0006] CN111378627B discloses a monoclonal antibody, a kit and an application of Golgi protein 73. The GP73 antibody mentioned in the patent is also prepared using the hybridoma cell method, and a polypeptide is used as an immunogen for animal immunization, which results in the inability of the prepared antibody to recognize all epitopes of the GP73 protein, affecting the type and specificity of the produced antibodies. The detection method of the kit mentioned in the patent is enzyme-linked immunosorbent assay, which has a long detection time of about 90 minutes, and the whole is manually operated, which is prone to human errors. The linear range of the ELISA kit developed based on the antibody is 1ng / ml-475ng / ml, and its linear range is small. In addition, the patent also lacks the necessary description of obtaining the epitopes covered by the GP73 monoclonal antibody.

[0007] Single-chain antibody (scFv) is a recombinant antibody formed by splicing the variable region genes of the heavy and light chains of an antibody through a connecting peptide. scFv has the advantages of small molecular weight, strong tissue penetration, short in vivo circulation half-life, low immunogenicity, and easy genetic engineering improvement. It plays an important role in the clinical diagnosis, treatment, and prevention of diseases. Summary of the invention

[0008] The present invention prepares two GP73 protein scFv antibodies by phage display technology, which not only saves a lot of preparation time, but also the detection products developed based on the scFv antibodies have a wider linear range and better detection sensitivity compared with similar products, and are simple to operate, the detection time does not exceed 30 minutes, and the detection results are more stable and reliable. Comprehensive experimental data show that the GP73 protein scFv antibodies prepared by phage display in the present invention and the derived kits have better performance.

[0009] The purpose of the present invention is to provide two strains of GP73 protein scFV antibodies (SGA-1 and SGA-2) with high affinity prepared by phage display technology.

[0010] The present invention provides a scFv antibody, characterized in that:

[0011] The sequences of CDR1 to CDR3 of the heavy chain variable region are TYAMS, VISSGSSYTYYPDSVKG, and EGELHYYAMD, respectively;

[0012] The sequences of CDR1 to CDR3 of the light chain variable region are VASSSVSSYLH, TTSSLASG, and HQYHRSPYT, respectively;

[0013] or the sequences of CDR1 to CDR3 of the heavy chain variable region are VASSSVSSYLH, TTSSLASG, and HQYHRSPYT, respectively;

[0014] The sequences of CDR1 to CDR3 of the light chain variable region are KSSQSLLYSDGKTYLIWLI, LVSKLDSGVP, and YQGTHFPYT, respectively.

[0015] Preferably, the heavy chain variable region is:

[0016] ESGGGLVKPGGSLKLSCAASGFTFSTYAMSWVRLTPEKRLEWVAVISSGSSYTYYPDSVKGRFTISRDNVKSTLYLQMSS LRSEDTAMYYCARNWEGELHYYAMDYWGQGTS;

[0017] The light chain variable region is:

[0018] QSPAIMSASLGERVTMTCVASSSVSSYLHWYQQKPGSSPKLWVYTTSSLASGVPARFSGSGSGTSYSLTINNMEAEDAAT YFCHQYHRSPYTFGGGTK;

[0019] Or its heavy chain variable region is:

[0020] QSGPALVKPGASVKMSCKASGYTFTSYVIHWVKQKPGQGLERIGWIWPYNDGTKFNEKFKGKATLTSDKSSSTAYMELSS LTSEDSAVYYCSSQQLAYWGQGTT;

[0021] The light chain variable region is:

[0022] QTPLTLSVTIGQPASISCKSSQSLLYSDGKTYLIWLIQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLRISRVEA EDLGVYYCYQGTHFPYTFGGGTK.

[0023] Specifically, the linker between the heavy chain and the light chain is GGSSRSS.

[0024] The present invention also provides a kit containing the scFv antibody.

[0025] Specifically, it is a chemiluminescent kit. Preferably, it is a magnetic particle chemiluminescent kit.

[0026] More specifically, it includes immunomagnetic beads RM; coating antibody; detection antibody; calibrator 1; calibrator 2; quality control product 1; quality control product 2;

[0027] The coating antibody is a biotin-labeled mouse anti-GP73 protein scFv antibody, and the detection antibody is an acridinium ester-labeled mouse anti-GP73 protein scFv antibody;

[0028] The calibrator is GP73 protein antigen liquid used to calibrate the standard curve on the machine, and the quality control is GP73 protein antigen liquid used for sample quality control.

[0029] Specifically, the concentrations of the calibrators were 300 and 100 mg / ml, and the concentrations of the quality controls were 150 and 50 mg / ml.

[0030] In a specific embodiment, the immunomagnetic beads RM are superparamagnetic particles covalently bound to high-purity streptavidin and suspended in PBS buffer to prepare a magnetic particle solution, preferably a magnetic particle solution with a concentration of 1 mg / mL.

[0031] More specifically, it includes:

[0032] One bottle of immunomagnetic beads RM, 4.2ml / bottle;

[0033] One bottle of coating antibody, 11.2ml / bottle;

[0034] One bottle of detection antibody, 11.2ml / bottle;

[0035] Calibrator 1, 1 ml / bottle;

[0036] Calibrator 2, 1 ml / bottle;

[0037] Quality control product 1, 1 ml / bottle;

[0038] Quality control product 2, one bottle, 1ml / bottle.

[0039] One of the keys of the present invention is to use phage display method to prepare GP73 protein scFV antibody. Different from the common hybridoma cell production of antibodies on the market, this method can not only save a lot of time, but also the prepared antibody has excellent antigen binding performance as tested by us.

[0040] The present invention selects the complete human GP73 protein sequence as an immunogen to immunize mice by analyzing the full-length sequence of human Golgi protein 73 (GP73). After the immunization cycle, the B cells of the mice are collected, the total RNA is extracted and reverse transcribed to generate cDNA. The VH and VL genes are amplified using human-specific antibody primers, and the scFv gene fragments are prepared by overlapping PCR. After the scFv gene fragments are fused with the pCANTAB-5E phagemid, they are electrotransfected into TG1 Escherichia coli, and the helper phage VCSM13 is added for overnight culture to construct a GP73 protein scFv antibody phage display library. After multiple rounds of screening, phages that can recognize GP73 protein antigens are retained, and the scFv antibodies expressed by these phages are identified by mass spectrometry. Combined with sequence analysis, the GP73 protein scFv antibodies that meet the requirements are expressed and purified for preliminary identification, and are used to prepare a detection kit to detect GP73 in human serum.

[0041] The beneficial effects of the present invention are as follows: ① In the prior art, some immunogens are fragments / polypeptides, which will result in limited types and specificity of antibodies produced, while we use full-length fragments for immunization, which produces more types of antibodies and recognizes richer epitopes of GP73; ② The present invention adopts a phage display method to prepare antibodies, which not only saves a lot of time, but also saves a lot of manpower and material resources compared to the hybridoma method on the market, and the antibodies produced by this method can avoid the HAMA effect, in simple terms, the effect is better when recognizing human proteins; ③ The GP73 protein scFv antibody obtained in the present invention not only retains the antigen binding site of the original monoclonal antibody, has high affinity and specificity, but also has better tissue permeability and faster blood clearance rate due to its small molecular weight (usually 25-30kDa), and is suitable for the treatment and diagnosis of tumors or deep tissue targets. ④ The linear range of the GP73 antibody obtained by phage display and its derived magnetic microparticle chemiluminescence kit is wider, 0.1-1000ng / ml (the linear range in the CN111378627B patent is 1ng / ml-475ng / ml), and the operation time is shorter, 30 minutes (CN101735319B is 70 minutes, CN111378627B is 90 minutes) BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 : Linear range of the kit.

[0043] Figure 2 . ROC curve of magnetic particle chemiluminescence kit for GP73scFv antibody. DETAILED DESCRIPTION

[0044] Example 1 Two GP73 protein scFv antibodies were prepared using phage display technology.

[0045] 1) Construction of GP73 protein immunogen.

[0046] Primers were designed based on the human full-length GP73 gene sequence, and the full-length GP73 sequence was amplified by PCR using cDNA as a template. EcoR I and Xba I sites were introduced at both ends of the sequence, and recombined with the vector pcDNA3.1-His plasmid. The obtained recombinant plasmid was transformed into Escherichia coli, and the bacterial solution was collected after amplification and culture for induced expression. Purified soluble GP73 protein was obtained after nickel column affinity chromatography for subsequent animal immunization.

[0047] 2) Construction of GP73 protein scFv phage antibody library.

[0048] Five BALB / c mice aged 6-8 weeks and weighing about 20g were selected for immunization. The antigen content of the first immunization was controlled at 0.1mg / mouse. The next immunization was performed one week later, and four rounds were continued. The purpose was to stimulate their immune system to produce specific antibodies to the antigen. After the last immunization, the mouse serum was collected to test the antibody titer, and the measured value was 6×10 5 After immunization, 30 mg of mouse spleen tissue was collected for RNA extraction and reverse transcription to obtain immune information containing all GP73 antigens in lymphocytes. VH and VL genes were amplified using specific primers of human antibodies, and VH and VL fragments were purified and recovered. Linker primers were then used for overlap PCR to splice the recovered full set of VH and VL genes into scFV genes. The scFv genes were then connected to the pCANTAB-5E phagemid vector and introduced into Escherichia coli TG1 by electroporation. Finally, a library with a capacity of 6.0×10 7 Antibody library of fully human GP73 protein.

[0049] The E. coli containing the GP73 antibody information and the phage are mixed according to the concentration ratio. In this step, 50ul of VSCM13 helper phage is used, and the phage concentration should be 50 times that of the E. coli concentration. After the infection, overnight culture is required, and the supernatant is precipitated with PEG8000 / NaCl and collected for subsequent screening and identification.

[0050] 3) Screening and identification of anti-GP73 protein scFv antibodies.

[0051] The ELISA plate was coated with the previously purified GP73 protein, and the constructed antibody library was subjected to 3-5 rounds of "adsorption-elution-enrichment". Monoclones were randomly selected from the screened bacterial colonies and identified by phage-ELISA. The phages that can recognize the GP73 protein antigen were retained, and after multiple rounds of panning, two scFv antibodies with different nucleic acid sequences were finally obtained, named SGA-1 and SGA-2. (The antibody gene sequence is shown in Table 1) Combined with sequence analysis, the expression and purification of the GP73 protein scFv antibodies that meet the requirements were preliminarily identified, and used to prepare a detection kit to detect GP73 expression in human serum.

[0052] Table 1. Amino acid sequences of two scFv antibodies

[0053]

[0054]

[0055] Example 2 is a magnetic particle chemiluminescence kit comprising the above-mentioned GP73 protein scFv antibody.

[0056] This example prepares a Golgi protein 73 (GP73) magnetic microparticle chemiluminescence immunoassay kit (50 servings) containing the present invention, and its composition includes:

[0057] One bottle of immunomagnetic beads (RM), 4.2 ml / bottle;

[0058] One bottle of coating antibody (R1), 11.2 ml / bottle;

[0059] One bottle of detection antibody (R2), 11.2 ml / bottle;

[0060] Calibrator 1 (CAL1), 1 ml / bottle;

[0061] Calibrator 2 (CAL2), 1 ml / bottle;

[0062] Quality control product 1 (QC1) one bottle, 1ml / bottle;

[0063] Quality control product 2 (QC2), one bottle, 1ml / bottle.

[0064] (1) Immunomagnetic beads (RM):

[0065] The immunomagnetic beads (RM) are superparamagnetic particles covalently bound to high-purity streptavidin and suspended in PBS buffer to prepare a magnetic particle solution with a concentration of about 1 mg / mL.

[0066] (2) Biotin-labeled mouse anti-GP73 protein scFv antibody (R1):

[0067] The biotin-labeled mouse anti-GP73 protein scFv antibody (R1) is conjugated with the scFv antibody SGA-1 by biotin, and the two are added at a molecular ratio of 20:1. After incubation at room temperature for 1 hour, desalting and purification are performed to remove free biotin, and the R1 component is diluted to a concentration of 0.5-1ug / mL and stored at 2-8°C in the dark.

[0068] (3) Acridinium ester labeled mouse anti-GP73 protein scFv antibody (R2):

[0069] The acridinium ester-labeled mouse anti-GP73 protein scFv antibody (R2) uses acridinium ester to combine with the scFv antibody SGA-2 amino group to generate an antibody with a fluorescent signal. The two are added in a molecular ratio of 5-10:1, incubated at room temperature for 1 hour, desalted and ultrafiltered to remove free acridinium ester, diluted to a concentration of 0.5-1ug / mL to prepare the R2 component, and stored at 2-8°C in the dark.

[0070] (4) Protein calibrators (CAL1 and CAL2)

[0071] The protein calibrator is prepared by dissolving different concentrations of GP73 antigen in diluent, and its concentration is 100ng / ml and 300ng / ml (referred to as CAL1 and CAL2 respectively), and its purpose is mainly to calibrate / correct the master curve. The liquid protein standard contains a freeze-dried product of protein stabilizer and preservative, with a pH of 7.2±0.2.

[0072] (5) Protein controls (QC1 and QC2)

[0073] The protein control product is prepared by dissolving different concentrations of GP73 antigen in diluent, and its concentration is 50ng / ml and 150ng / ml (referred to as QC1 and QC2 respectively). Its purpose is mainly for quality control, and the measured concentration value of the quality control product should be within the target value range. The liquid protein standard contains a freeze-dried product of protein stabilizer and preservative, with a pH of 7.2±0.2.

[0074] Example 3 Quality detection of the magnetic microparticle chemiluminescence kit containing the above-mentioned GP73 protein scFv antibody.

[0075] (1) Evaluation of linearity: The high-value samples close to the upper limit of the linear interval were diluted to at least 5 concentrations according to a certain ratio, among which the low-value concentration samples must be close to the lower limit of the linear interval. Each concentration of the sample was tested 3 times, and the average value was calculated. The average value and the dilution ratio were fitted with a linear line using the least squares method, and the linear correlation coefficient r was calculated. The linear correlation coefficient r = 0.9998 was obtained, and the linear range was 0.1ng / ml to 1000ng / ml. The results are shown in Table 1 and Figure 1 .

[0076] Table 2 Linear evaluation results

[0077]

[0078] (2) Accuracy evaluation: A known high-concentration GP73 sample (A) was added to a low-concentration serum B. The volume ratio of the added sample A to the added sample B was 1:9. The above mixed solution and serum B were tested three times each, and the average value was taken. The calculated recovery rate was 99.81%. The results are shown in Table 2.

[0079] Table 2 Accuracy evaluation:

[0080]

[0081]

[0082] (3) Precision test of the kit: Three batches of reagents were used for precision experiments. High / low value standards were used for the tests respectively. Each batch was measured 20 times to calculate the coefficient of variation of the concentration. The results are shown in Table 3 below. The results show that the coefficient of variation is less than 5%.

[0083] Table 3 Precision evaluation results

[0084]

[0085] (4) Evaluation of the limit of blank (LOB): The relative light unit (RLU) of the zero-value calibrator was measured 20 times, and the RLU values ​​(relative luminescence values) of the 20 measurement results were obtained. The mean (M) and standard deviation (SD) were calculated, and the RLU value corresponding to M+2SD was obtained. The RLU value corresponding to M+2SD was substituted into the calibration curve equation of the calibrator used in the kit, and the corresponding concentration value was obtained as the limit of blank. The limit of blank was <0.04 ng / mL. The results are shown in Table 4.

[0086] Table 4 Evaluation results of blank limit:

[0087]

[0088] (5) Evaluation of the limit of detection (LOD): The low-value serum samples were diluted to theoretical concentrations of 0.05, 0.1, 0.15, 0.2, and 0.25, respectively, in ng / mL, ranging from 1 to 5 times the blank limit concentration, and were numbered (B1, B2, B3, B4, and B5). Five low-concentration samples were tested with the GP73 chemiluminescence assay kit for three consecutive days, and each sample was tested four times. The LoD value was calculated based on the test results. The detection limit was <0.05 ng / mL. The results are shown in Table 5.

[0089] Table 5 Evaluation results of detection limit:

[0090]

[0091]

[0092] (6) Evaluation of limit of quantitation (LOQ): The low-value serum samples were diluted to theoretical concentrations of 0.05, 0.1, 0.2, 0.3, and 0.4 ng / mL, respectively, and numbered (C1, C2, C3, C4, and C5). Five low-concentration samples were tested with the GP73 chemiluminescence assay kit for three consecutive days, and each sample was tested four times. The LoQ value was calculated based on the test results. It was shown that at 0.1 ng / mL, TE met the accuracy target of ≤25%. The results are shown in Table 6.

[0093] Table 6 Evaluation results of quantitation limit:

[0094]

[0095] (7) Evaluation of specificity: The kit was used to detect human serum albumin at a concentration of 1 mg / ml, alpha-fetoprotein (AFP) at a concentration of 2700 ng / ml, and glypican 3 (GPc3) at a concentration of 500 ng / ml. The test was repeated 3 times for each concentration. The detection results were ≤1.0 ng / ml, with no significant interference. The results are shown in Table 7.

[0096] Table 7 Specificity evaluation results:

[0097]

[0098]

[0099] (8) Stability: The reagents were placed in an oven at 2-8°C and 37°C for 7 days and 14 days, and the relative luminescence value (RLU) decay rates of the test calibrators and clinical samples were all <5%. The results are shown in Table 8.

[0100] Table 8 Evaluation results of stability:

[0101]

[0102] Example 4 Clinical sample validation of the magnetic microparticle chemiluminescence kit containing the above-mentioned GP73 protein scFv antibody.

[0103] A total of 1,852 clinical samples were collected in this study, and the receiver operating characteristic curve (ROC curve) method was used to confirm the critical value of the magnetic particle chemiluminescence kit for GP73 protein scFv antibody for result judgment. The conformity of the positive and negative samples determined by the gold standard with the gold standard diagnosis at the optimal threshold was evaluated.

[0104] The detailed selection information is shown in Table 9.

[0105] Table 9 Description of research samples

[0106] Hospital Name Normal sample number Number of liver cirrhosis samples total Hunan Provincial People's Hospital 544(53.1%) 480(46.9%) 1024 Hunan Cancer Hospital 464(55.9%) 364(44.0%) 828 total 1008(54.4%) 844(45.6%) 1852

[0107] Table 10 Description of baseline demographic data

[0108]

[0109]

[0110] Note: Q1: 25th percentile; Q3: 75th percentile

[0111] Table 11 Descriptive analysis of GP73 measurement results:

[0112]

[0113] Note: Q1: 25th percentile; Q3: 75th percentile

[0114] SPSS Statistics 26.0 statistical software was used to calculate the ROC curve. The results are shown in Figure 2 , AUC area, optimal cutoff, 95% CI and other values ​​are shown in Table 12.

[0115] Table 12 Calculation results of ROC curve of magnetic microparticle chemiluminescence kit for GP73 monoclonal antibody

[0116] serial number Statistics Sample size Positive samples = 844, negative samples = 1008 Optimal Threshold (Cutoff) 3.49 (sensitivity = 94.79%; specificity = 97.32%) Youden Index J 0.923 AUC area 0.986 Standard error Se 0.0132 95% CI 0.982-0.990

[0117] *AUC: Area under the ROC curve

[0118] It can be seen from Table 12 that the area under the ROC curve of the test reagent is 0.986, which has a good diagnostic value. The highest Youden index J value is 0.923, and the corresponding concentration value is 3.49 ng / mL. The sensitivity at the optimal threshold of 3.49 ng / ml is 94.79%; the specificity is 97.32%.

[0119] Comparison with gold standard, analysis of compliance rate, sensitivity and specificity

[0120] In this test, 800 samples of 844 liver cirrhosis samples were tested positive, 44 samples were tested negative, and the sensitivity was 800 / 844=94.79%; 981 samples of 1008 healthy samples were tested negative, 27 samples were tested positive, the specificity was 981 / 1008=97.32%, and the total compliance rate was (981+800) / 1852=96.17%. The results are shown in Table 13.

[0121] Table 13 Gold standard and test reagent pairing test results

[0122]

[0123] Table 14. Kappa consistency test statistical results

[0124] serial number Statistics PA, Pe, Kappa value 0.9276, 0.5048, 0.9226, Kappa value ≥ 0.75, good consistency Standard error 0.0202 95% CI upper limit 0.9622 95% CI lower limit 0.8830 Test value Z Z=12.5027,Probability value P<0.0001 Test results P < 0.05, reject H0, Kappa value comes from a non-zero population .

Claims

1. A scFv antibody, characterized in that: The sequences of CDR1 to CDR3 of the heavy chain variable region are TYAMS, VISSGSSYTYYPDSVKG, and EGELHYYAMD, respectively; The sequences of CDR1 to CDR3 of the light chain variable region are VASSSVSSYLH, TTSSLASG, and HQYHRSPYT, respectively; or the sequences of CDR1 to CDR3 of the heavy chain variable region are VASSSVSSYLH, TTSSLASG, and HQYHRSPYT, respectively; The sequences of CDR1 to CDR3 of the light chain variable region are KSSQSLLYSDGKTYLIWLI, LVSKLDSGVP, and YQGTHFPYT, respectively.

2. The scFv antibody according to claim 1, characterized in that The heavy chain variable region is: ESGGGLVKPGGSLKLSCAASGFTFSTYAMSWVRLTPEKRLEWVAVISSGSSYTYYPDSVKGRFTISRDNVKSTLYLQMSSLRSEDTAMYYCARNWEGELHYYAMDYWGQGTS; Its light chain variable region is: QSPAIMSASLGERVTMTCVASSSVSSYLHWYQQKPGSSPKLWVYTTSSLASGVPARFSGSGSGTSYSLTINNMEAEDAATYFCHQYHRSPYTFGGGTK; Or the heavy chain variable region thereof is: QSGPALVKPGASVKMSCKASGYTFTSYVIHWVKQKPGQGLERIGWIWPYNDGTKFNEKFKGKATLTSDKSSSTAYMELSSLTSEDSAVYYCSSQQLAYWGQGTT; Its light chain variable region is: QTPLTLSVTIGQPASISCKSSQSLLYSDGKTYLIWLIQRPGQSPKRLIYLVSKLDSGVPDRFTGSGSGTDFTLRISRVEAEDLGVYYCYQGTHFPYTFGGGTK.

3. The scFv antibody according to claim 1, characterized in that The linker between the heavy chain and the light chain is GGSSRSS.

4. A kit comprising the scFv antibody according to any one of claims 1 to 3.

5. The kit according to claim 4, characterized in that It is a chemiluminescent kit.

6. The kit according to claim 5, characterized in that It is a magnetic particle chemiluminescence kit.

7. The kit according to claim 6, characterized in that include Immunomagnetic beads RM; coating antibody; detection antibody; calibrator 1; calibrator 2; quality control product 1; quality control product 2; The coating antibody is a biotin-labeled mouse anti-GP73 protein scFv antibody, and the detection antibody is an acridinium ester-labeled mouse anti-GP73 protein scFv antibody; The calibrator is GP73 protein antigen liquid used to calibrate the standard curve on the machine, and the quality control is GP73 protein antigen liquid used for sample quality control.

8. The kit according to claim 7, characterized in that The concentrations of the calibrators were 300 and 100 mg / ml, and the concentrations of the quality controls were 150 and 50 mg / ml.

9. The kit according to claim 7 or 8, characterized in that The immunomagnetic beads RM are superparamagnetic particles covalently bound to high-purity streptavidin and suspended in PBS buffer to prepare a magnetic particle solution, preferably a magnetic particle solution with a concentration of 1 mg / mL.

10. The kit according to claim 9, characterized in that include One bottle of immunomagnetic beads RM, 4.2ml / bottle; One bottle of coating antibody, 11.2ml / bottle; One bottle of detection antibody, 11.2ml / bottle; Calibrator 1, 1 ml / bottle; Calibrator 2, 1 ml / bottle; Quality control product 1, 1 ml / bottle; Quality control product 2, one bottle, 1ml / bottle.

Citation Information

Patent Citations

  • Anti-GP73 monoclonal antibodies and methods of obtaining the same

    CN105189549A

  • Anti-GP73 monoclonal antibodies and methods of obtaining the same

    CN110240653A

  • Golgi apparatus protein 73 monoclonal antibody, kit and application

    CN111378627A

Cited By

  • Antibody 3E11 of human Golgi apparatus membrane protein GP73, antibody composition and application

    CN119613543A